Colorado News Desk

Eczema Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, AstraZeneca, Kyowa Kirin, and Others

 Breaking News
  • No posts were found

Eczema Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, AstraZeneca, Kyowa Kirin, and Others

December 06
21:08 2023
Eczema Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, AstraZeneca, Kyowa Kirin, and Others

DelveInsight’s, “Eczema Pipeline Insight 2023” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Eczema pipeline landscape. It covers the Eczema pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Eczema pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Eczema Pipeline Report

  • DelveInsight’s Eczema pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Eczema treatment.
  • The leading companies working in the Eczema Market include Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc., Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others.
  • Promising Eczema Pipeline Therapies in the various stages of development include alitretinoin, Arctiva, KY1005, Dupilumab, Lebrikizumab, Baricitinib, MEDI9929, Midazolam, Omeprazole, and others.
  • December 2023: LEO Pharma announced a study of Phase 3 clinical trials for Tralokinumab. The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema. This will be judged by a range of assessments that rate the severity and extent of atopic hand eczema and its symptoms, as well as general health status and quality of life.
  • November 2023: Regeneron Pharmaceuticals announced a study of Phase 4 clinical trials for Dupilumab. The study is focused on skin of color participants who have moderate-to-severe atopic dermatitis. Atopic dermatitis, also referred to as eczema, is a condition that causes the skin to become itchy, dry, and cracked. From the previous studies on the study drug, it is seen that the study drug has an acceptable safety and effectiveness in participants with atopic dermatitis. The aim of this study is to get additional information on the safety and effectiveness of the study drug, particularly the information on aspects of atopic dermatitis in skin of color participants.

 

Request a sample and discover the recent advances in Eczema Treatment Drugs @ Eczema Pipeline Outlook Report

 

In the Eczema pipeline report, a detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Eczema collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Eczema Overview

Eczema, also known as atopic dermatitis, is the most common form of dermatitis. Genetic as well as environmental factors are thought to play a part in the pathogenesis. Eczema is most commonly seen in children but can be seen in adults. People with the disease tend to have dry, itchy skin that is prone to infection.

 

Find out more about Eczema Treatment Landscape @ Drugs for Eczema Treatment

 

Eczema Emerging Drugs Profile

  • Amlitelimab: Kymab
  • BX 005: BiomX
  • LP 0145: LEO Pharma

 

Eczema Pipeline Therapeutics Assessment

There are approx. 100+ key companies which are developing the therapies for Eczema. The Eczema companies which have their Eczema drug candidates in the most advanced stage, i.e. phase II include, LEO Pharma.

 

DelveInsight’s Eczema Pipeline Report covers around 100+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Eczema pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Eczema Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Learn more about the emerging Eczema Pipeline Therapies @ Eczema Clinical Trials Assessment

 

Scope of the Eczema Pipeline Report

  • Coverage- Global
  • Eczema Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Eczema Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Eczema Companies- Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc., Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others.
  • Eczema Pipeline Therapies- alitretinoin, Arctiva, KY1005, Dupilumab, Lebrikizumab, Baricitinib, MEDI9929, Midazolam, Omeprazole, and others.

 

Dive deep into rich insights for new drugs for Eczema Treatment, Visit @ Eczema Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Eczema: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Eczema– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug name : Company name
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Amlitelimab: Kymab
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Drug name : Company name
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name : Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Eczema Key Companies
  21. Eczema Key Products
  22. Eczema- Unmet Needs
  23. Eczema- Market Drivers and Barriers
  24. Eczema- Future Perspectives and Conclusion
  25. Eczema Analyst Views
  26. Eczema Key Companies
  27. Appendix

 

For further information on the Eczema Pipeline Therapeutics, reach out @ Eczema Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/behcets-disease-market

Categories